Literature DB >> 12047009

Combination antipsychotics: pros, cons, and questions.

Alexander L Miller1, Catherine S Craig.   

Abstract

In prescription surveys, use of combination antipsychotics is common and is increasing, despite little supporting evidence. This article highlights potential problems with using combination antipsychotics, discusses paths to their maintenance use, and reviews the efficacy evidence. Paths to maintenance antipsychotic combinations include (1) failure or patient refusal of all reasonable monotherapies, (2) indefinite continuation of combinations initially intended to be brief, (3) trials of combinations in preference to reasonable monotherapy trials, and (4) addition of a second antipsychotic to counteract a problem (safety, tolerability, or adherence) arising during successful monotherapy. Virtually all of the evidence on combination antipsychotics is on augmentation of clozapine, with only one randomized controlled trial. Research on combination antipsychotics is sorely needed. Designing clinical trials is made difficult by the very large numbers of possible combinations and doses. It may be feasible to analyze existing data bases to identify combinations that appear particularly promising to investigate.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12047009     DOI: 10.1093/oxfordjournals.schbul.a006912

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  15 in total

1.  Drug treatment modalities in psychiatric inpatient practice: a 20-year comparison.

Authors:  Corrado Barbui; Arcangelo Ciuna; Michela Nosè; Deborah Levi; Margherita Andretta; Scott B Patten; Francesco Amaddeo; Michele Tansella
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-19       Impact factor: 5.270

2.  Trends in adult antipsychotic polypharmacy: progress and challenges in Florida's Medicaid program.

Authors:  Robert J Constantine; Ross Andel; Rajiv Tandon
Journal:  Community Ment Health J       Date:  2010-01-23

3.  Association of antipsychotic polypharmacy with health service cost: a register-based cost analysis.

Authors:  Lone Baandrup; Jan Sørensen; Henrik Lublin; Merete Nordentoft; Birte Glenthoj
Journal:  Eur J Health Econ       Date:  2011-03-31

Review 4.  Augmentation strategies in clozapine-resistant schizophrenia.

Authors:  Gary Remington; Amitabha Saha; Siow-Ann Chong; Chekkera Shammi
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

5.  Polypharmacy in the management of patients with schizophrenia on risperidone in a tertiary-care hospital in Malaysia.

Authors:  Sa Jacob; Mi Mohamed Ibrahim; F Mohammed
Journal:  Ment Health Fam Med       Date:  2013-01

6.  Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior.

Authors:  Christoph U Correll; Ladan Shaikh; Juan A Gallego; Jeffrey Nachbar; Vladimir Olshanskiy; Taishiro Kishimoto; John M Kane
Journal:  Schizophr Res       Date:  2011-03-21       Impact factor: 4.939

Review 7.  Challenges and opportunities in measuring the quality of mental health care.

Authors:  Amy M Kilbourne; Donna Keyser; Harold Alan Pincus
Journal:  Can J Psychiatry       Date:  2010-09       Impact factor: 4.356

Review 8.  Antipsychotic polypharmacy in schizophrenia: benefits and risks.

Authors:  Thomas R E Barnes; Carol Paton
Journal:  CNS Drugs       Date:  2011-05       Impact factor: 5.749

9.  Polypharmacy with antipsychotic drugs in patients with schizophrenia: trends in multiple health care systems.

Authors:  FangFang Sun; Eileen M Stock; Laurel A Copeland; John E Zeber; Brian K Ahmedani; Sandra B Morissette
Journal:  Am J Health Syst Pharm       Date:  2014-05-01       Impact factor: 2.637

10.  Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study.

Authors:  Fuminari Misawa; Keiko Shimizu; Yasuo Fujii; Ryouji Miyata; Fumio Koshiishi; Mihoko Kobayashi; Hirokazu Shida; Yoshiyo Oguchi; Yasuyuki Okumura; Hiroto Ito; Mami Kayama; Haruo Kashima
Journal:  BMC Psychiatry       Date:  2011-07-26       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.